RSV-F vaccine + seasonal TIV

RSV-F vaccine + seasonal TIV refers to the coadministration of a respiratory syncytial virus (RSV) prefusion F protein-based subunit vaccine and a seasonal trivalent or quadrivalent inactivated influenza (TIV/QIV) vaccine. The RSV-F component is a protein subunit or recombinant protein that contains stabilized prefusion F antigens from both RSV A and B strains. It stimulates active immunity by inducing neutralizing antibodies against the fusion glycoprotein of the virus, thereby preventing lower respiratory tract disease caused by RSV[5][6]. The most widely used brands for this are Abrysvo (Pfizer) and Arexvy (GSK), both approved for adults over 60 years old and certain high-risk populations[3][5]. Seasonal TIV is an inactivated influenza virus vaccine targeting circulating strains of influenza A and B viruses. Coadministration studies show that giving these vaccines together is immunologically non-inferior for most strains but may result in slightly lower antibody titers; clinical significance remains unclear[8].

Brand names

AbrysvoArexvy

Other names

RSV preF vaccinequadrivalent inactivated influenza vaccinetrivalent inactivated influenza vaccine